Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Autotreinamento assistido por computador para melhorar a função executiva (COMPEX)

29 de setembro de 2026 atualizado por: Hanne Christensen, Bispebjerg Hospital

Computer-Assisted Self-Training to Improve Executive Function Versus Unspecific Training in Patients After Stroke, Cardiac Arrest or in Parkinson's Disease: A Randomized Controlled Trial

This project explores the effects of specialized computer-based cognitive rehabilitation (CBCR) targeting executive functions in three groups of patients: Stroke, Cardiac Arrest and Parkinson's Disease. The effect of specialized CBCR is compared to generally cognitively stimulating activities on a computer

Visão geral do estudo

Descrição detalhada

This project explores the effects of specialized computer-based cognitive rehabilitation (CBCR) targeting executive functions in three groups of patients: Stroke, Cardiac Arrest and Parkinson's Disease. The effect of specialized CBCR is compared to completing generally cognitively stimulating activities on a computer. A total of 307 patients is expected to be enrolled. All patients will complete a neuropsychological test battery assessing executive functions at inclusion, directly after the eight-week training period and at follow-up three months after the end of the intervention period. Furthermore, all patients will answer questionnaires concerning quality of life and ADL-measures at baseline, after the intervention and at follow-up. All patients will train for a period of 8 weeks, 5 times a week for 60 minutes regardless of their group allocation.

Tipo de estudo

Intervencional

Inscrição (Estimado)

307

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Copenhagen, Dinamarca
        • Rigshospitalet
      • Copenhagen, Dinamarca
        • Bispebjerg Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 100 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • A diagnose of stroke, cardiac arrest or Parkinson's disease.
  • Aged 18 years or older.
  • Impaired working memory measured with CABPad working memory test, cut off for inclusion: 5 symbols or less backwards
  • Computer and internet access at home.
  • Providing informed consent.

Inclusion criteria specific for stroke

  • Inclusion within 6 months post-stroke
  • Stroke confirmed by clinical findings and imaging, both AIS and ICH is allowed.
  • Initial stroke severity >/= NIHSS 3.

Inclusion criteria specific for cardiac arrest

• Inclusion within 6 months post ictus.

Inclusion criteria specific for Parkinson's disease

  • Clinical diagnosis of PD.
  • Anti-parkinsonian medical treatment (dopaminergic or other).

Exclusion Criteria:

  • Informed consent not provided
  • Other neurological or psychiatric disease which is expected to influence the patient's ability to participate in the trial according to the investigator
  • Not able to participate according to investigator

Exclusion criteria specific for stroke

  • Patients with massive anosognosia for executive dysfunction or patients with no subjective feeling of executive dysfunction (Patient sustains total denial of executive symptoms over time)
  • Patients with severe aphasia, in which it is unclear whether the patient's performance on a neuropsychological test-battery is due to aphasia and not executive dysfunction.

Exclusion criteria specific for cardiac arrest • None

Exclusion criteria specific for PD

• Diagnosis of PD Dementia according to the MDS PD Dementia criteria

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Specific computer-based cognitive rehabilitation

154 patients will be allocated to specific computer-based cognitive rehabilitation. This group will train with 10 exercises from the cognitive rehabilitation software 'Scientific Brain training PRO'. These 10 exercises are designed to train various executive functions.

CBCR are software-programmes for computers which are clinically developed for rehabilitation of various cognitive functions.

Comparador Ativo: General computer-based cognitive stimulation

154 patients will be allocated to general computer-based cognitive stimulation. This group will train with 10 generally mentally stimulating games on a website specifically designed for this trial. These 10 games are chosen because they are believed to have a low load on executive functions but stimulate over-all concentration and visuoperceptual abilities.

For this trial we have developed a webpage for general cognitive stimulation, which is designed to provide general computer-based cognitive stimulation.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
CABPad Working Memory Test
Prazo: After the end of the intervention (8 weeks after baseline)

Test of working memory. The higher score the better (theoretically infinite score)

After the end of the intervention (8 weeks after baseline)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
CABPad Working Memory Test - 3 months follow-up
Prazo: At follow-up visit 3 months after end of intervention

Test of working memory. The higher score the better (theoretically infinite score)

At follow-up visit 3 months after end of intervention
Minimum Data Set-Home Care- Instrumental Activities of Daily Living (MDS-HC-IADL)
Prazo: At follow-up visit 3 months after the end of the intervention

Questionnaire concerning activities of daily living. 0-3 points on an 8-item scale, the fewer points the better.

At follow-up visit 3 months after the end of the intervention
Trail Making A
Prazo: Directly after the intervention, eight weeks after inclusion

Test of processing speed and visual attention. The lower score the better (theoretically infinite score)

Directly after the intervention, eight weeks after inclusion
Trail Making A
Prazo: At follow-up visit 3 months after the end of the intervention

Test of processing speed and visual attention. The lower score the better (theoretically infinite score)

At follow-up visit 3 months after the end of the intervention
Trail Making B
Prazo: Directly after the intervention, eight weeks after inclusion

Test of divided attention, mental flexibility. The lower score the better (theoretically infinite score)

Directly after the intervention, eight weeks after inclusion
Trail Making B
Prazo: At follow-up visit 3 months after the end of the intervention

Test of divided attention, mental flexibility. The lower score the better (theoretically infinite score)

At follow-up visit 3 months after the end of the intervention
SDMT
Prazo: Directly after the intervention, eight weeks after inclusion

Symbol Digit Modalities Test: Test of mental speed. The higher score the better (theoretically infinite score)

Directly after the intervention, eight weeks after inclusion
SDMT
Prazo: At follow-up visit 3 months after the end of the intervention

Symbol Digit Modalities Test: Test of mental speed. The higher score the better (theoretically infinite score)

At follow-up visit 3 months after the end of the intervention
Phonological verbal fluency test
Prazo: Directly after the intervention, eight weeks after inclusion

Test of verbal phonological fluency. The higher score the better (theoretically infinite score)

Directly after the intervention, eight weeks after inclusion
Phonological verbal fluency test
Prazo: At follow-up visit 3 months after the end of the intervention

Test of verbal phonological fluency. The higher score the better (theoretically infinite score)

At follow-up visit 3 months after the end of the intervention
Categorical verbal fluency test
Prazo: Directly after the intervention, eight weeks after inclusion

Test of verbal categorical fluency. The higher score the better (theoretically infinite score)

Directly after the intervention, eight weeks after inclusion
Categorical verbal fluency test
Prazo: At follow-up visit 3 months after the end of the intervention

Test of verbal categorical fluency. The higher score the better (theoretically infinite score)

At follow-up visit 3 months after the end of the intervention
Fear questionnaire
Prazo: Directly after the intervention, eight weeks after inclusion

Questionnaire with 24 items concerning fear on a scale from 0 to 8 where 8 indicates a higher degree of avoidance due to fear

Directly after the intervention, eight weeks after inclusion
Fear questionnaire
Prazo: At follow-up visit 3 months after the end of the intervention

Questionnaire with 24 items concerning fear on a scale from 0 to 8 where 8 indicates a higher degree of avoidance due to fear

At follow-up visit 3 months after the end of the intervention
mrs: Modified Rankin Scale
Prazo: Directly after the intervention, eight weeks after inclusion

Questionnaire concerning disability on a scale from 0 (no symptoms) to 6 (dead): Higher score indicates more severe disability.

Directly after the intervention, eight weeks after inclusion
mrs: Modified Rankin Scale
Prazo: At follow-up visit 3 months after the end of the intervention

Questionnaire concerning disability on a scale from 0 (no symptoms) to 6 (dead). Higher score indicates more severe disability.

At follow-up visit 3 months after the end of the intervention
IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly)
Prazo: Directly after the intervention, eight weeks after inclusion

Cognitive decline in the elderly, reported by partner. A scale of 16 items from 1 (much better) to 5 (much worse). Higher score indicates more severe disability.

Directly after the intervention, eight weeks after inclusion
IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly)
Prazo: At follow-up visit 3 months after the end of the intervention

Cognitive decline in the elderly, reported by partner. A scale of 16 items from 1 (much better) to 5 (much worse). Higher score indicates more severe disability.

At follow-up visit 3 months after the end of the intervention
EuroQol-5 domain (EQ-5D-5L)
Prazo: Directly after the intervention, eight weeks after inclusion

Quality of life scale with 5 domains, each rated from 1-5 indicating slight to severe disability . Higher score indicates more severe disability. Completed by patient and partner

Directly after the intervention, eight weeks after inclusion
EuroQol-5 domain (EQ-5D-5L)
Prazo: At follow-up visit 3 months after the end of the intervention

Quality of life scale with 5 domains, each rated from 1-5 indicating slight to severe disability. Higher score indicates more severe disability. Completed by patient and partner

At follow-up visit 3 months after the end of the intervention
PDQ 39 (Parkinsons Disease Questionnaire: Only in patients with Parkinson Disease)
Prazo: Directly after the intervention, eight weeks after inclusion

Quality of Life questionnaire in patients with Parkinson's Disease. A scale with 39 items rated from 1 (never) to 5 (all the time / Can not do at all). Higher score indicates more severe disability.

Directly after the intervention, eight weeks after inclusion
PDQ 39 (Parkinsons Disease Questionnaire: Only in patients with Parkinsons Disease)
Prazo: At follow-up visit 3 months after the end of the intervention

Quality of Life questionnaire in patients with Parkinson's Disease. A scale with 39 items rated from 1 (never) to 5 (all the time / Can not do at all). Higher score indicates more severe disability.

At follow-up visit 3 months after the end of the intervention
Compliance
Prazo: Directly after the intervention, eight weeks after inclusion

Monitoring of total time spent training in minutes

Directly after the intervention, eight weeks after inclusion
PHQ-9 (Patient health questionnaire 9)
Prazo: Directly after the intervention, eight weeks after inclusion

Questionnaire about health of patient with 9 items rated on a 4 point scale from 0 (not at all) to 3 (almost every day). Higher score indicates more severe disability.

Directly after the intervention, eight weeks after inclusion
PHQ-9 (Patient health questionnaire 9)
Prazo: At follow-up visit 3 months after the end of the intervention

Questionnaire about health of patient with 9 items rated on a 4 point scale from 0 (not at all) to 3 (almost every day). Higher score indicates more severe disability.

At follow-up visit 3 months after the end of the intervention
2) visual analogue scale (1-10)
Prazo: Directly after the intervention, eight weeks after inclusion

After last session: how much they liked doing the training and if they would recommend the intervention to somebody else in their situation. Higher score indicates they liked the training more.

Directly after the intervention, eight weeks after inclusion
Minimum Data Set-Home Care- Instrumental Activities of Daily Living (MDS-HC-IADL)
Prazo: Directly after the intervention, eight weeks after inclusion

Questionnaire concerning activities of daily living. 0-3 points on an 8-item scale, the fewer points the better.

Directly after the intervention, eight weeks after inclusion

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de junho de 2020

Conclusão Primária (Estimado)

5 de novembro de 2026

Conclusão do estudo (Estimado)

5 de fevereiro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

3 de janeiro de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de janeiro de 2020

Primeira postagem (Real)

14 de janeiro de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

This is currently undecided

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever